Tevogen CEO Says ‘Actively Evaluating’ Potential Acquisitions

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.
Global stock market chart and trading board - stock photo
Representative image of stock market chart on a glowing particle world map and trading board. (Photo by Yuichiro Chino/Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Published Mar 06, 2026   |   4:02 PM EST
Share
·
Add us onAdd us on Google

Tevogen CEO Ryan Saadi said in a letter to shareholders on Friday that the company is “actively evaluating” potential acquisitions to drive value.

“If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time,” the CEO said.

As per the CEO, the combined entities under consideration for acquisition may generate aggregate annual revenues in excess of $50 million. The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.

Get updates to this developing story directly on Stocktwits.

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy